Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RGC ~ From Providing Grants To Over 10,000 Children With ADHD, ASD And COVID-19, To Building A Company To Save And Improve Lives, This CEO Could Be Taking Philanthropy To A New Level https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
$RGC Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial https://finance.yahoo.com/news/regencell-bioscience-standardized-formulae-shown-131500297.html
$RGC’s Company Ownership average stock price
Understanding and looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.
A high insider ownership often makes company leadership more mindful of shareholder interests. Small Cap stock, **Regencell Bioscience Holdings** (RGC) insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. (A positive indication)
We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Regencell Bioscience Holdings.
This counter is worth to put on your watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Regencell Bioscience Holdings.
Yat-Gai Au, Founder of the company, who spent a stonking US$1.2m on stock at an average price of US$25.23.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Yat-Gai Au purchased 68.34k shares over the year. The average price per share was US$26.03.
$RGC Big buying opportunity down here https://schrts.co/tsNxbihH
Defensive Strategy for Downtrend Market
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC EZPZ Squeeze Stock like GME!
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience healthcare company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC CEO Letter to Shareholders
Dear Shareholders:
As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond.
For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”).
We have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. We aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. We are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
**Research Studies**
Our first study using personalized TCM formula in Hong Kong showed a drop in assessment scores meaning that ADHD and ASD symptoms were less severe for patient who participated in the study. However, there is no assurance that we can expect similar outcome in our second research study.
Encouraged by this positive outcome, we plan to commence our second research study next month in Hong Kong, which is expected to last for approximately one year. Approximately 100 patients will participate in our second research study, in 3-12 months treatment cycles. Our goal for the second research study is to verify the effectiveness of the standardized TCM formulae with candidates that are experiencing mild, moderate and severe ADHD and ASD conditions. Once completed, the research study will provide the foundation for the Company to apply for a proprietary Chinese medicine (“pCm”) registration in Hong Kong. We look forward to sharing the outcome as soon as we complete the study.
During a short period of time, we have achieved significant milestones, and these could not have been achieved without the tremendous backing of our long-time supporters. Speaking on behalf of our entire management team and board of directors, I would like to extend my thanks and deepest gratitude to:
**Mr. Samuel Chen and Mrs. Fiona Chen, Dr. Hai Ping Jin and Mr. Jay Lee** for their contribution and support to our research. Their investment gives hope to ADHD and ASD patients, their families and caregivers in need of a solution.
Also, **Mr. Sik-Kee Au**, our strategic TCM research partner, for offering his 30+ years of experience in TCM research & development, and clinical practice. Our partnership with Mr. Au has been instrumental in conducting our studies and has given us the exclusive rights and ownership of all his TCM formulae and the intellectual property rights of the TCM formulae.
Last but not least, I would like to thank all of our business partners, professionals and investors for making this possible, and to our team for the amazing work they continue to do every day.
[https://www.businesswire.com/news/home/20210805005564/en/Regencell-Bioscience-Holdings-Limited-Releases-CEO-Letter-to-Shareholders]
$RGC, a Short Squeeze potential like $GME
Fellow Redditors of Wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankruptcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
More so, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggressive or awarded traders could keep in their watchlist.
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
$RGC Healthcare Company holding against Bearish Market
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO and had seen fallen victim to short sellers and hedge funds which took the shares down. Recently the share price has rose over 30% . The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC Company Founder Buying Back Shares to Stop Short Sellers
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue to only draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until January 16th 2023.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
$RGC Defensive Play in Action and its Rising Stock Price
Investors who wishes to diversify their portfolio should look into defensive stocks ie. Healthcare, F&B and Utility as a defensive play towards current market volatility. Regencell Bioscience Holdings (RGC) is a healthcare company.
The company has seen a heavily beatdown during early months of Q2 of 2022, but is currently seeing a positive movement in the market price. Recently, the stock has seen a stellar rise of 30%.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Regencell Bioscience - a Traditional Chinese Medicine Company and Philanthropist CEO
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
The CEO's Conviction $RGC
Regencell Bioscience Holdings (RGC), a healthcare bioscience company, has been a topic of trend amongst traders and short sellers, who have seen its price take a beating a few months after its IPO last year.
The CEO (Mr. Au) has voiced his concerns that these negative sentiments are not only hurting the company but also investors and patients who are seeking treatments.
RGC’s business model is focused on using Traditional Chinese Medicine (TCM) to treat attention hyperactivity disorder ("ADD"), autism spectrum disorder ("ASD"), and COVID-19-like illnesses, and these negative FUD (Fear, Uncertainty, and Doubt) are obstacles to the company’s mission and goal.
These negative sentiments are strategies deployed by sophisticated hedge funds by using short selling and complex derivatives to take advantage of small investors.
In defense against these strategic ploys by these hedge funds, Mr. Au has agreed to only draw $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserves share options for all employees except himself.
Furthermore, Mr. Au’s personal funds will be used to buyback company shares to demonstrate his commitment to the company and to reposition against short and distort sellers. Based on publicly available data, the company believes there is a total cumulative short volume of over 19 million shares since the company’s IPO.
Mr. Au "I began my share purchases last year, using my personal funds in order to further our goal of saving and improving lives."
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Healthcare Bioscience Company - Regencell $RGC holding against raging markets
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO was consolidating between $20-$22 before its resistance breakout in May 22” and shown a bullish pattern in recent weeks. The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Looking into $RGC Regencell Bioscience. Company with strong management.
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
More so, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
TCM treatment for Covid19 Patient - Regencell Bioscience $RGC
Regencell Bioscience’s Traditional Chinese Medicine (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the company’s positive progress in medical, the CEO (Mr Yat-Gai au) has shown his confidence in the progress of the company direction and has yet to sold a single share since taking the company IPO. Mr Yat has also pledged to refrain from taking salary and bonus (<1$) until the company reaches US$1 Billion market cap.
https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html
$RGC CEO Buying Back Shares at average price of USD $26
The company CEO of Regencell Bioscience Holding (RGC) has been buying back shares over the year. (over 68.34k shares with average price of $USD26) which is not far from last night’s closing price at $USD$27.50 .
In fact, the company CEO (Mr Au) ‘s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html
$RGC: Regencell Bioscience - Defensive Stance in Downtrend Market
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
$RGC is a potential hidden healthcare company
The Forbes mags' shares the below advantages of holding a healthcare "Defensive" Company Share.
"1. As defensive stocks, healthcare companies provide steady returns in any market. Because people will always need healthcare, the healthcare sector provides very steady, consistent returns that are uncorrelated with the overall direction of the stock market.
2. The U.S. healthcare sector is growing faster than the rest of the economy. Growth in the sector is being propelled by technological advances, an aging population and improving treatments for chronic diseases and conditions.
3. Healthcare spending in the U.S. is seeing strong, sustained growth. National health spending is projected to grow at an average annual rate of 5.4% through 2028, reaching $6.2 trillion and 19.7% of the country’s GDP."
Aside from having a favorable position as a "defensive" healthcare company, RGC's management and CEO has taken a more transparent approach to the company's investors.
- Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx
$RGC Regencell Bioscience Limited | 5 About Us • We are an early - stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, with initial products in development for the treatment of ADHD and ASD • Our goal is to improve the lives of Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”) patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally Regencell Bioscience Holdings Limited (Cayman Islands) Regencell Limited (Hong Kong) Regencell Bioscience Limited (Hong Kong) TCM Practitioner (Mr. Sik - Kee Au) 100% 100% Strategic Partnership Regencell Bioscience Holdings Limited See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. I nve stments may be speculative, illiquid and there is a risk of loss.
https://sec.report/Document/0001213900-21-036122/
The company need to share video presentation. about the company
RGC historical data https://finance.yahoo.com/quote/RGC/history?p=RGC
RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
$RGC Need to show us of some company video clip
“Fed will push us into recession”
Economists have been raising their doubts in the FED’s capability in handling the rising inflation rate which is looking to fall of the edge into a oblivion recession.
As shared by economist Mohamed A. El-Erian “It is, unfortunately, uncomfortably possible that the Fed is going to slam on the brakes and push us into recession,” during his interview on Yahoo Finance Live in an online interview.
El-Erian’s also remarks that the Fed’s move last week in raising interest rates by 75 basis points (the most aggressive hike in decades) has made Wall Street strategist in notion for an economic slowdown.
The US Central bank was too late in acknowledging that inflation will become a problem and was not quick enough to reacting to the surging prices thus losing credibility in the eyes of wall street and also investors.
Losing credibility in the FED will lead to people doubting its projects, consequently leaving the people with skepticism and distrust towards the FED.
[https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html](https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html)
Investors are suggested to rotate their portfolio into defensive sectors which are known to be resilient towards times of economic recession ie. Healthcare, F&B, Utilities and REITs.
Regencell Bioscience Holdings , ticker $RGC is a bioscience healthcare company which had been listed in the NASDAQ market in USA. The company’s business is predominantly in the Research & Development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease esp. COVID-19, for which there are unmet holistic medical needs in the global market.
Since its inception into IPO last year July, the stock has seen a 300% rise. The stock has a Outstanding Shares of 13.01M and Floating Shares of 1.44M. The CEO is currently holding >80% of the company shares.
RGC share buyback by Company CEO/Philanthropist
RGC a healthcare company which has been on the target of shortsellers in Q2 22’ is taking on the full might of the company CEO.
Based on the the CEO’s Schedule 13D fillings with the SEC (US Security and Exchange Commission), CEO (Mr Au) has used an aggregate of $5.03 mil of his personal funds to purchase ordinary shares on open market between July 2021 and May 2022. A total of 10,539,159 ordinary shares are now owned by the Mr Au, which represents approximately 81% of company’s total issued and outstanding ordinary shares.
The company’s mission is to develop a natural treatment method for neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19.
Aside from RGC’s approach in developing successful treatments for ADHD and ASD, Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
RGC: Another counter in eyes of Short Sellers. Short Squeezers to Arms!
Short sellers have their sights set on Regencell (Nasdaq: RGC).
After taking the company IPO last year on July 2021, RGC became a victim for short-sellers where intraday volume often as high as 40% - 90% are recorded on certain days. According to the SEC, this coordinated pattern could be an indication of a possible “naked short” which took place strategically.
In comparison of numbers, RGC’s total reported cumulative short volume is > 19 million shares while its total reported short volume to outstanding shares ratio (excluding CEO and Chairman ownership) is 7.63x. RGC is more heavily shorted than GME (in fact almost double)
Company with strong management
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreover, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
Mr Au, the company’s CEO and chairman has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
Presently, the company’s business plan of expansion is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
&RGC Stock Price Movement
The Fed is hiking interest rates quickly in an attempt to calm rising inflation, which has affected many stock investors who are witnessing bleeding portfolios on their phones or PCs.
Companies are expected to cut profit forecasts in the coming quarter due to rising inflation rates and a potential decrease in earnings.
Investor Rick Rule told MoneyWise earlier this year, "I do not believe the broad equity market would take many rate rises."
The rule does not advocate selling all of one's holdings.
This takes us to a healthcare stock that had an IPO last year on July 22nd and had a terrific run of 300% capital gains after listing. Shares have taken a significant damage as a result of short sellers and hedge funds intentionally targeting the firm shares. RGC, on the other hand, has returned to the $30s, buoyed by positive research findings for Regencell's RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder contact, and market support for the shares.
The formulas proposed seek to treat the underlying causes of diseases while also easing symptoms and enhancing general health. RGC's TCM employs natural materials to treat diverse aspects in the body, and every physiological function is taken into account while formulating TCM formulations for patients.
Unlike other early-stage organisations, RGC has chosen a more open strategy that is well-aligned with shareholders' long-term interests.
Some highlights of the company's leaders and founders that demonstrate long-term commitment to the company:
- The CEO will get only a $1 yearly salary and no bonuses until the company's market valuation hits $1 billion.
- The CEO will continue to purchase back company shares to demonstrate his commitment to the firm and to strengthen its position against short and distort sellers.
- All directors and employees who were previously given stock options at the Company's IPO have agreed to a six-month lock-up following the vesting of their stock options. Because their stock options are slated to vest on July 16, 2022, their shares will be locked up until January 16, 2023.
RGC hopes to provide findings from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.
When the report is out, we will know if the firm has been making positive development on the company.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
An early Zoom investor was interested in another company #RGC.
Regencell Bioscience Limited (NASDAQ:RGC) is a bioscience and healthcare company that focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment, specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), as well as infectious diseases affecting people's immune systems such as COVID.
The stock price has increased by more than 300 percent since its IPO and saw a significant sell-off in mid-June, although it has recovered roughly 40% from its lows in June.
Of course, one of the greatest and strongest supporters of the business share is none other than the company) who believes in a better and brighter future for the firm.
In support of his dedication, belief, and position in the firm, the founder and CEO, (Mr Yat-Gai Au), has committed approximately $5 million dollars of his own reserves in purchasing back company shares to posture against probable short and distort sellers.
Mr Samuel Chen, a highly successful early **Zoom Video Communications, Inc.** investor, is another famous early RGC investor (Nasdaq: Zoom). Mr Samuel was the second largest individual investor, owning 8.8% of Zoom shares.
Mr. Au has so far converted his shareholders' loan of $3.25 million to Regencell's ordinary shares upon listing, vowed not to take more than $1 in pay and bonus until Regencell reaches a $1 billion market capitalization, and reserved share options for all workers except himself.
Furthermore, to demonstrate management's commitment to the firm, all directors and employees who were previously awarded stock options at Regencell's IPO have committed to a six-month lock-up period once their stock options become vested. Their shares will be locked up until January 16, 2023, since their stock options are slated to vest on July 16, 2022.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Live on SSN Network on the effectiveness of TCM in treating COVID19 #RGC
Regencell Bioscience Limited is a Hong Kong-based firm that is pioneering the use of Traditional Chinese Medicine ("TCM") to cure not just ADHD and ASD, but also the Covid-19 virus, which shocked the globe in 2020.
RGC now offers a therapy formula that has been tested on 19 individuals (suspected or confirmed COVID cases). After an average of 5 days of therapy, 12 of 19 patients showed signs of progress in their recovery.
[https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html](https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html)
Separately, while Mr Au, the business's CEO and chairman, was not present for the interview, he has been working behind the scenes to protect his company from recent short seller and trader attacks on the company's shares. Since the company's IPO, Mr Au has purchased nearly $5 million in stock.
"While research is still underway," Mr Au stated, "we are certain that our formula can make a difference in the fight against COVID-19."
Company CEO/Philanthropist buys back RGC shares
RGC, a healthcare business that was targeted by shortsellers in Q2 22', is facing the full force of the company CEO.
According to the CEO's Schedule 13D filings with the SEC (US Securities and Exchange Commission), the CEO (Mr Au) spent $5.03 million of his own cash to buy ordinary shares on the open market between July 2021 and May 2022. Mr Au currently owns a total of 10,539,159 ordinary shares, accounting for nearly 81% of the company's total issued and outstanding ordinary shares.
The company's objective is to provide a natural treatment technique for neurocognitive disorders and degenerations, notably ADHD and ASD, as well as viral illnesses that impair people's immune systems, such as COVID-19.
Aside from RGC's approach to developing successful treatments for ADHD and ASD, Mr Au has also been involved in his own philanthropic project (within his own means) that aims to provide care to over 10,000 affected children with ADHD, ASD, and Covid-19, as well as those affected by financial difficulties. Mr Au's programme has already benefitted over 150 youngsters since its inception on April 16, 22.
$RGC is defending itself against short sellers.
RGC has received a lot of short and unfavorable market commentary from sceptics. During this time, the company's CEO (Mr Au) has been purchasing back shares for $5 million.
Regencell Bioscience Holdings (RGC: Nasdaq) is a bioscience healthcare firm in the early stages that focuses on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
The firm has recently been on an upward trajectory, demonstrating its endurance in uncertain times, thanks to its main industry: healthcare.
Healthcare stocks, for example, have demonstrated through time that they are resistant to market volatility and are highly regarded by institutional investors and fund managers.
Despite being severely shorted in the early months of Q2 22', the firm stock has been on an upward trend despite the massive sell-off in several market sectors, particularly the growth stock and cryptocurrency markets.
$RGC is a possible undervalued healthcare firm.
The Forbes mags' shares the below advantages of holding a healthcare "Defensive" Company Share.
"1. As defensive stocks, healthcare companies provide steady returns in any market. Because people will always need healthcare, the healthcare sector provides very steady, consistent returns that are uncorrelated with the overall direction of the stock market.
2. The U.S. healthcare sector is growing faster than the rest of the economy. Growth in the sector is being propelled by technological advances, an aging population and improving treatments for chronic diseases and conditions.
3. Healthcare spending in the U.S. is seeing strong, sustained growth. National health spending is projected to grow at an average annual rate of 5.4% through 2028, reaching $6.2 trillion and 19.7% of the country’s GDP."
Aside from having a favourable position as a "defensive" healthcare company, RGC's management and CEO has taken a more transparent approach to the company's investors.
- Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx
The majority of 2021 IPOs failed. This is the prize winner
2021 was the busiest year for deals since 2000, with a record-breaking IPO rush of 1,035 listings in the US, with the biotech and healthcare sectors leading the way, accounting for 36% of all IPO activity.
While most investors are busy reviewing stocks in their current portfolio, it may come as a surprise which company came in first for stock return. Although it is currently not a household name, any savvy investor should keep this stock on their radar: Regencell Bioscience $RGC
RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
A June 2022 article mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
RGC’s Solid Foundation
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
Comparison to 2022 IPO Top Performer
A recent stock that has gone to the moon since its mid-July 2022 IPO is AMTD Digital ,$HKD.
The controlling shareholder, AMTD Group Company Limited, was founded by billionaire Li Ka-shing’s CK Hutchison Holdings Limited in 2003. HKD’s IPO price was $7.80 and has gained over 9,000% since, closing at $ $30.42 on October 11, 2022.
https://www.benzinga.com/general/biotech/22/08/28316977/a-look-into-the-top-performing-ipo-stock-of-2021
Regencell CEO Yat-Gai Au has created an organization that is about more than profits -- it's about changing lives. His aim is to change the way patients are treated
Human genius grows from humble origins.
Yat-Gai Au developed Regencell Bioscience to help more people benefit from natural and holistic medicines, with the objective of ensuring that everyone has equitable access to such therapy for many years to come.
Several individuals have made significant contributions to RGC's overall performance during the previous few years. Dr. Chao (Chief Medical Officer) and James Chung (Chief Operating Officer), who joined Regencell in 2015 and 2019, respectively, were motivated by their own experiences with TCM and the significant improvements they saw in ADHD and ASD patients.
"For our organisation to remain loyal to what we believe in and continue to move in the correct path, we must surround ourselves with the appropriate individuals who share our values and interests. Our staff creates plans and supervises scientific testing to verify that our services and products are effective, safe, and beneficial "Yat-Gai concurs.
The organisation has evolved into more than merely a research and development institution for neurocognitive diseases and degenerations. "It is opening the path for exceptional advancements in TCM to become commonplace. Why should these ground-breaking therapies be limited to a restricted set of individuals or communities?"
The results of a recent clinical trial, the EARTH Trial, revealed that RGC-COV19TM is an effective solution for the relief and eradication of COVID-19 symptoms within 6 days. As a result, the chances of hospitalisation and mortality are reduced. TCM and traditional medicine have been demonstrated to be successful in a hyper-modern, tech-driven environment through rigorous experiments.
Keeping it intimate and close
Although RGC's clinical trials will still need to be peer-reviewed in the coming months, there is significant market interest because the firm has created a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that seeks to make a difference wherever feasible, and while our R&D may be confined to a few sectors of interest, we will be able to widen our perspectives to more complicated therapies over time," Yat-Gai quickly remarks.
Regencell received net funds of $22.7 million from its IPO, investments that aided the company's access to the tools and resources required to expedite clinical research.
Yat-Gai has found that after the company became public, short and distorting groups or people have begun to impact their stock price and mood. "Enterprises like ours are not given the opportunity to establish themselves because the offenders are pushing down the value of smaller companies, leading the market and general public to lose faith. This harms our firm, notably the patients, some of whom are yearning for a solution "he stated.
Yat-Gai was able to acquire over $5.9 million in regular firm shares to assist reduce the detrimental consequences of such short-term strategies. Yat-Gai Au currently holds an 81% ownership in the firm. Other owners possess around 19% of the remaining shares.
"To date, I have invested millions of dollars of my personal funds on RGC stock. My most recent acquisition was $886,000 in RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the firm and its future, and I aim to continue putting my money where my mouth is by increasing my shareholdings."
Because majority ownership is kept within the firm, often known as 'Insider Ownership,' it allows them to have greater influence over crucial decision-making concerns, which can assist accelerate the company's overall development goals.
"The decision to continually acquire RGC shares over the last several months is to support and ensure the company's promise may be realised for years to come. We've invested a lot of time, energy, and money in Regencell, and we're fully aware of the potential difference it can make in the area of alternative medicine. I feel that if I lead the way, our organisation will be able to reach the goals we've set for ourselves in the next years."
Long-term transactions not only provide the firm more control over important decision-making, but also allow them to increase investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
As investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years.
One company of interest in this specific category is Regencell Bioscience Holdings Limited (NASDAQ:RGC), an early-stage bioscience company focusing on the research, development, and commercialization of Traditional Chinese Medicine ("TCM").
Regencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19.
The bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million.
RGC has kept investors interested and has received media attention for all the right reasons; the most recent - the company's chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to purchase ordinary RGC shares through the open market to support the growth and potential of the company.
Sizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade.
Why $RGC?
RGC is not ordinary, and in many ways, we can see why investors have started noticing the company.
So far, year-to-date share prices have increased by 17.03% while the Nasdaq Biotechnology Index has only gone up by 2.69%. On average, share prices are zig-zagging between $34.79 and $35.84, and some investors have set up their year range closer to $59.00 per share.
For the six months between July 2021 and December 2021, the company reported a basic diluted loss per share of $0.29, compared to $0.03 for the same period of 2020.
The loss could be attributed to the company's sudden increase in operating expenses, which jumped from $368,465 for the 6 months ending December 31, 2020, to $3,658,906 for the same period in 2021, an increase of roughly 893%.
The company reported cash availability of $19 million in December 2021, compared to $0.06 million in June 2021. The main source of cash came from net proceeds of the company's IPO, including proceeds from the sales of over-allotment shares, totaling approximately 22.7 million.
Initially, when the company went public back in July 2021, share prices were well below their current levels, and a month later, in August 2021, share prices jumped as much as 204% in a single trading session. Since going public, Regencell has treated more than 88 COVID patients with over 94% effectiveness in eliminating symptoms within 6 days; they have ongoing ADHD/ASD clinical studies and were included in the MSCI world microcap index. RGC was also one of the top best-performing stocks on Nasdaq in 2021, according to www.stockanalysis.com.
Late last year, Regencell entered preliminary trials for ADHD/ASD. During this time, the stock was trading in the low $20's range. By mid-February 2022, share prices had climbed over $40 before scaling down to the $20's range.
Although market conditions have been volatile and investor sentiment negative, RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company's RGC-COV19 TCM formula.
From our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.
The promising track record and positive clinical results have kept investors interested as RGC has remained relatively stable and resolute in its performance. For investors who can digest small purchases a lot better, RGC could outpace sluggish market conditions.
https://seekingalpha.com/article/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience
$RGC Regencell CEO Shares His Vision, Insights And Aims To Change The Way Patients Are Treated https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
Humble beginnings lead to human ingenuity
Yat-Gai Au founded Regencell Bioscience so that more people can benefit from natural and holistic treatments with a goal to provide everyone equal access to such treatment for many years to come.
Throughout the last few years, several people have largely contributed to the overall success of RGC. James Chung (Chief Operating Officer) and Dr. Chao (Chief Medical Officer), who joined Regencell in 2015 and 2019, respectively, were inspired by their personal experience with TCM and the major improvements they saw on ADHD and ASD patients.
"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.
The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"
In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
Keeping it close and personal
Although the clinical studies completed by RGC will still need to be peer-reviewed in the coming months, there's been growing interest from the market as the company has built quite a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that looks to make a difference where it's possible, and while our R&D may be limited to a few fields of interest, over time we'll be able to broaden our perspectives to more complex treatments," Yat-Gai briefly mentions.
Through its IPO, Regencell had net proceeds of $22.7. million, investments that helped grow the company's access to the tools and resources needed to fast-track clinical studies.
Since the company went public, Yat-Gai has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment. "Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.
To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.
"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."
Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.
"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."
The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Understanding how floating stocks work
"A company's float is an important number for investors because it indicates how many shares are actually available to be bought and sold by the general investing public," says Tim Speiss, co-partner in charge of the Personal Wealth Advisors Practice with EisnerAmper LLP. "Low -loat stocks typically have higher [bid-ask] spreads and higher volatility than a comparable larger float stock."
Quick tip: A bid-ask spread is the difference between how much someone will buy a security for (bid price) and how much someone else is willing to sell it for at any particular time (ask price). The smaller the bid-ask spread, the better. High-float stocks tend to have a narrow bid-ask spread, while low-float stocks often have a much wider gap.
What are low-float stocks?
While there's no industry-wide standard for what defines low-float stocks, Speiss says, many brokers consider stocks with fewer than 10 million freely available shares for trading to be a low float.
For example, Nortech Systems Incorporated currently trades on the New York Stock Exchange with 2.66 million outstanding shares. Of that, 1.16 million shares are floating. Only about 44% of this stock is available for public trading. The majority of this stock is owned by either major investors, employees, or company insiders, making it a low float.
Smaller floats like this are subject to large swings in value from news impacting a company's finances, the popularity of products, and other changes that can influence demand. According to Nasdaq, Sequential Brands' low float stock experienced a 104.57% increase in price between July 1 and 6, 2021, in spite of reports bankruptcy may be around the corner for the company. Trade volume spiked from nearly 34,000 shares on July 1 to around 13 million on July 6. Just two days later, the stock price dropped 27% and trading volume slowed to 728,000 shares.
This kind of volatility can present opportunities to buy and sell shares to quickly make money, but it isn't generally compatible with long-term investment strategies. Because the value of low-float stocks can be so unpredictable, there can be considerable risk attached to investing in them. Also, low-float stocks are in short supply, which can make it difficult to buy or sell them. The bid-ask spread may be much higher than you would find with a high-float stock as a result.
As mentioned before, companies may decide to increase their float by issuing new shares as a way to raise capital or encourage more trading. But they may also choose to reduce their float through a stock buyback, which can result in increasing the value of shares. This usually happens if the company believes its shares have been discounted too much, wants to invest in itself, or wants to see its financial ratios go up.
"A stock buyback is a way for a company to reinvest in itself," Speiss explains. "The repurchased shares are absorbed by the company and the number of outstanding shares in the market is reduced. Because there are fewer shares on the market post buyback, the relative ownership stake of each investor increases."
Quick tip: If you're interested in investing in low-float stocks, it's important to keep a very close eye on how it performs. Stock prices and volumes can rise and fall drastically several times within a single day. To make sure you're buying and selling at the right time, you need to constantly monitor the market.
Shares outstanding
Shares outstanding are the total shares of stock a company has. It includes the restricted and closely held shares, as well as the ones available for trade, whereas float refers only to the number of shares available for trading.
It's important to look at and understand how much the total stock is so you can calculate whether the float is high, low, or in the middle. You can find outstanding shares and float statistics on most investing websites and indexes. Subtract the float from the outstanding shares to find how many shares are not available for trading. That will help you better evaluate what kind of float a stock has and whether investing in it might fit into your overall strategy.
Every investor in Regencell Bioscience Holdings Limited (NASDAQ:RGC) should be aware of the most powerful shareholder groups. With 81% stake, individual insiders possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And looking at our data, we can see that insiders have bought shares recently. This could signal that stock prices could go up and insiders are here for it.
Yat-Gai Au founded Regencell Bioscience so that more people can benefit from natural and holistic treatments with a goal to provide everyone equal access to such treatment for many years to come.
Throughout the last few years, several people have largely contributed to the overall success of RGC. James Chung (Chief Operating Officer) and Dr. Chao (Chief Medical Officer), who joined Regencell in 2015 and 2019, respectively, were inspired by their personal experience with TCM and the major improvements they saw on ADHD and ASD patients.
"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.
The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"
In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
Although the clinical studies completed by RGC will still need to be peer-reviewed in the coming months, there's been growing interest from the market as the company has built quite a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that looks to make a difference where it's possible, and while our R&D may be limited to a few fields of interest, over time we'll be able to broaden our perspectives to more complex treatments," Yat-Gai briefly mentions.
Through its IPO, Regencell had net proceeds of $22.7. million, investments that helped grow the company's access to the tools and resources needed to fast-track clinical studies.
Since the company went public, Yat-Gai has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment. "Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.
To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.
"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."
Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.
"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."
The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.
https://www.businessinsider.com/personal-finance/stock-float
https://pro.benzinga.com/blog/how-to-find-low-float-stocks/
https://finance.yahoo.com/news/81-regencell-bioscience-holdings-limited-105517095.html
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Things to Consider When Analyzing Small-Cap Stocks.
Management Quality: A competent management team is essential for any company, let alone a smaller one trying to establish itself in the market. Potential investors should undertake some basic online research on the key people within the company, such as the CEO and chief financial officer (CFO). Do they have a track record of running successful businesses? Also, see if the leadership team owns shares in the company. Company insiders owning stock indicates a commitment to success and aligns their interests with those of the shareholders.
Growing Sales: Small-cap companies typically have limited cash flow—therefore, they must generate healthy sales. As a rule of thumb, small-cap investors should look for stocks with an annual revenue growth rate of at least 20%, which indicates that a company has the potential for disruptive innovation within its industry and is well positioned to generate a future profit. Investors can find this information on Yahoo! Finance under the "Financials" tab, which shows a company's revenue for the past three years.
High Operating Margins: A company's operating margin represents how efficiently it can generate profit through its primary operations before paying interest and tax. When investing in small caps, it is a good idea to look for consistently increasing operating margins, as this indicates that a company is good at turning sales into profits.
Advantages of Small-Cap Stocks
Growth Potential: Small-cap stocks provide investors with significant upside by getting in early before a company potentially goes on to become an industry leader. Moreover, small-cap stocks with a market capitalization of under $1 billion can double in value much easier than companies like Amazon or Apple that have $1 trillion-plus market caps, as it takes far less money to move their share price. Additionally, a small-cap stock that goes on to realize rapid growth can gain the attention of Wall Street analysts and institutional investors, which can increase shareholder returns even further.
Less Competition from Larger Investors: Institutional investors, such as banks, hedge funds, and REITs, typically stick to investing in large-cap stocks, often overlooking many small-cap opportunities. This allows retail investors to buy the story of a future company of tomorrow without competing with traditional Wall Street money.
One ticker that has a small market cap ($412.35M) and a CEO who is holding 81% of the stock is Regencell Bioscience ($RGC).
To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. With 81% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
Let's take a closer look to see what the different types of shareholders can tell us about Regencell Bioscience Holdings.
What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company.
https://www.investopedia.com/investing/top-small-cap-stocks/
Sometimes, investors buy stocks with heavy short interest to exploit the potential for a short squeeze, but the attempt to swing for the fences sometimes ends in disaster.
A short squeeze is an unusual condition that triggers rapidly rising prices in a security due to short sellers being forced to cover their positions by buying shares. For a short squeeze to occur, the security must have an unusual degree of short-sellers holding positions in it.
Generally, a rapid rise in the stock price could be attractive, but it is not without risks. Here’s how it works: Active traders monitor highly shorted stocks and watch for them to start rising. If the price picks up momentum, the trader jumps in to buy, trying to catch what could be a short squeeze and a significant move higher.
Short squeezes are arguably always a gamble. Over the years, some stocks have moved higher after they had a heavy short interest, while in other instances, they tumbled miserably.
RGC Short Interest Compared To GameStop?
The short squeeze of American video game retailer GameStop Corp.
GME in January 2021 took the market by storm, causing major financial consequences for some hedge funds and large losses for short-sellers.
Roughly 140% of the game retailer’s public float had been sold short. There was a mad rush to buy shares to cover those positions, which caused the price to rise further.
Although a number of hedge funds participated, the short squeeze was largely triggered by users of the subreddit r/wallstreetbets.
At the height of that episode, on January 28, 2021, the short squeeze caused the retailer’s stock price to reach a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of that month.
One ticker that some traders have looked at to also have short squeeze potential is Regencell Bioscience Ltd.
RGC
The short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year. In fact, Regencell has sometimes been more heavily shorted than GameStop, with occasional days close to 90% shorted.
Although Regencell and GameStop stocks’ short volume profiles might be considered to be similar, not as much is known about Regencell. As of May 16, the company’s founder and CEO held 10,539,159 ordinary shares, representing 81% of the total number of issued and outstanding ordinary shares in Regencell.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price. Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52. Where are all the extra shares coming from?
As witnessed on Reddit and other social media and forums, especially during the GameStop short squeeze, retail shareholders came together, driven by the community’s effort to punish market participants who make a living shorting and distorting public companies, causing them to stumble and fall.
CEO’s Conviction In RGC
Regencell Founder and CEO Yat-Gai Au’s believes in a better and brighter future for the company. He says he has demonstrated his commitment and confidence and his position against possible short and distort sellers by using his own money, amounting to over $5 million, to purchase Regencell shares. Moreover, he has support from Samuel Chen, a very successful early Zoom Video Communications, Inc. investor. Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing. He has also pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
Additionally, to demonstrate commitment to Regencell, all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Whether or not the ticker will encounter a short squeeze is anyone’s guess, but some traders are keeping their eyes on a host of companies that seem to have outsized short interests.
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
The amount of bearish bets against Hong Kong stocks has risen to levels that could trigger a surge in share prices as traders rush to close out their positions, according to quantitative analysts at Morgan Stanley.
Hedge funds and other short sellers say they’re either covering bearish wagers or planning to do so, strategist Gilbert Wong wrote in emailed comments Wednesday. Short-selling activity was running at just under 20% of total turnover on the city’s stock market this week, a level not seen since May, calculations by Bloomberg based on exchange data showed.
“We believe the risk of short squeeze in China and Hong Kong equities is rising,” Wong said. “Stay alert.”
Betting against Hong Kong’s stock market has proven to be a profitable trade this year, with the Hang Seng Index down over 20% at its low point in March on fears of an economic slowdown and regulatory overreach. Global investors are so underweight Chinese assets that bearish equity bets were considered one of the most-crowded trades in Bank of America Corp.’s investor survey earlier this year.
But it can also be a perilous one -- in the middle of that month, a coordinated pledge from China’s top regulators to address investor concerns triggered a two-day, 17% surge in the benchmark.
Theories on what could lead to a rebound this time range from beaten-down valuations, low positioning after August redemptions and signs of increased stimulus from Beijing. The Hang Seng climbed as much as 3.3% Thursday after China announced additional measures to boost infrastructure spending. The Hang Seng Tech index rallied 5.3%, with Alibaba Group Holding Ltd. surging 8.1%.
While short-covering flows may have little to do with fundamental changes in the outlook for Chinese equities, some investors are behaving like the best of the bearish-China trade is behind them.
“They believe further market downside is limited from current levels because positioning is low and very defensive,” said Wong.
One ticker that is Hong Kong based, that some traders have looked at to also have short squeeze potential is Regencell Bioscience Ltd.
The short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year. In fact, Regencell has sometimes been more heavily shorted than GameStop, with occasional days close to 90% shorted.
Although Regencell and GameStop stocks’ short volume profiles might be considered to be similar, not as much is known about Regencell. As of May 16, the company’s founder and CEO held 10,539,159 ordinary shares, representing 81% of the total number of issued and outstanding ordinary shares in Regencell.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price. Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52. Where are all the extra shares coming from?
As witnessed on Reddit and other social media and forums, especially during the GameStop short squeeze, retail shareholders came together, driven by the community’s effort to punish market participants who make a living shorting and distorting public companies, causing them to stumble and fall.
https://www.bloomberg.com/news/articles/2022-08-25/hong-kong-short-squeeze-is-rising-risk-for-morgan-stanley-quants
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
Why This Biotech Stock Is Worth A Shot
RGC launched a follow-up research for their experimental liquid formula RGC-COV19TM in the treatment of COVID-19 symptoms on May 18, 2022. (EARTH-B Trial). The second study expanded on the encouraging findings from the initial EARTH experiment (EARTH-A Trial), which was carried out in 2020–2021. In the two studies, 95.5 percent of the participants (n=81) reported complete symptom relief six days after therapy, with the exception of occasional coughing and loss or reduction in sensation of taste and/or smell (sensory dysfunction).
RGC anticipates publishing data from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.
In order to set standards for therapy, dosing, adverse effects (AEs), and assessing patient response in a methodical and reproducible manner, Regencell Bioscience's initial clinical study was created. Seven adolescents with clinically confirmed ASD or ADHD, ranging in age from five to eleven, participated in the 2018–2019 study. Subjects got a personalised TCM formula for up to three months after stopping all current treatments and medications. Parental interviews and four validated assessment tools, such as the Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS), and Pelham (SNAP)-IV 26-item Parent Rating Scale, were used to gauge the responses of the patients (SNAP-IV-26). During the course of treatment, all seven patients showed a reduction in symptoms on all four scales.
The second clinical trial assesses how three standardized TCM formula mixes (for mild, moderate, and severe impairment) respond to children in the same age group. Weekly practitioner meetings, twice daily medication for three to twelve months, and monthly assessments are all part of the study's design. The outcomes will be used to submit a proprietary Chinese medicine (pCm) registration application in Hong Kong, making the product available for purchase both over the counter and in other clinic.
To support its findings, Regencell is concentrating on its clinical research. Through these initiatives, the infrastructure for manufacturing and the supply chain that is needed to obtain pCm registration will be built. The commercialization of Regencell Bioscience's standardised formulations and pCm registration in Hong Kong are both subject to a four-year timeline. A lot of tasks lie ahead for the company:
•Finishing its second clinical trial and reviewing outcomes.
• Running more clinical studies to support the use of its patented formulas for ASD/ADHD and other uses.
• Getting IP protection in Hong Kong and other markets through the acquisition of patents and other types of IP.
• Setting up a manufacturing infrastructure and supply chain that complies with registration criteria.
• Compiling and filing paperwork for pCm approval.
• Develop the infrastructure and marketing and distribution plan.
We are encouraged by RGC's thoughtful, methodical approach to developing its therapies and communicating its progress to shareholders, which we believe may be a sign of greater things to come as it moves towards commercialization. RGC's steady share price ascent in recent weeks.
• Completing its second clinical trial and evaluating results.
• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
• Obtaining patents and other forms of IP protection in Hong Kong and other markets.
• Establishing manufacturing capability and supply chain that will meet registration requirements.
• Assembling and filing documentation for pCm approval.
• Build out its marketing and distribution strategy and infrastructure.
•
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.
https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html
Biotech stocks could be a big opportunity for exponential gains
Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stocks market. And for biotech stock investors, this could be a big opportunity for exponential gains.
Regencell Bioscience, an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.
The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund for the second research study (currently ongoing), TCM formulae and products, staff salaries, product and intellectual property registrations, facilities rental, renovations and equipment, for working capital and other general corporate purposes.
Regencell Bioscience $RGC; Upcoming results in follow-on study of ASD/ADHD treatment formula.
Founded in 2014, Hong Kong-based Regencell Bioscience (NASDAQ:RGC) is an early clinical stage bioscience company using Traditional Chinese Medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases such as the coronavirus disease (COVID-19).
Regencell Bioscience is expected to report results of a follow-on study for its ASD/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.
The formula is based on the “Sik-Kee Au TCM Brain Theory®” that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain. As we discussed earlier, this hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.
Regencell Bioscience’s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients’ response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.
As a customized formula is designed to suit each patient’s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula. Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.
Path to registration and commercialization
Regencell Bioscience has a four-year timeframe to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:
• Completing its second clinical trial for ASD/ADHD and COVID, and evaluating results.
• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
• Obtaining patents and other forms of IP protection in Hong Kong and other markets.
• Establishing manufacturing capability and supply chain that will meet registration requirements.
• Assembling and filing documentation for pCm approval.
• Build out its marketing and distribution strategy and infrastructure.
We believe that an emphasis on conducting well-designed clinical trials that measure outcomes based on well-established assessment instruments, will provide Regencell Bioscience with a competitive advantage in terms of expertise and credibility in an industry that is moving towards higher standards for efficacy, safety and quality. While there is still much work to do, in our view, Regencell Bioscience is taking a thoughtful, systematic approach to developing its TCM formulae.
https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html?guccounter=1&guce_referrer=aHR0cHM6Ly9rZWVwLmdvb2dsZS5jb20v&guce_referrer_sig=AQAAAJUD3LXLIHsU8iLYDxujMiuklkHij3sauxd7hYyUmY0-x56FaELKmIMmT54roEpSW_8EwnyhOrR8X9AjAfos7RAJ-4zzEQRxY9Zaa3pJ3K3_j7-umkaN3crXyBeSSm1Wjx5dWoA0aIwn6fMvD8GAOmw7h-b5SiLYlbKikylxU6N-
$RGC Regencell CEO Shares His Vision, Insights And Aims To Change The Way Patients Are Treated https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
3 Reasons Why Companies Buy Back Stocks
Investopedia, 2019.
Stock Buybacks Preserve the Stock Price
Shareholders usually want a steady stream of increasing dividends from the company. And one of the goals of company executives is to maximize shareholder wealth. However, company executives must balance appeasing shareholders with staying nimble if the economy dips into a recession.
Why do some favor buybacks over dividends? If the economy slows or falls into recession, a company might be forced to cut its dividends to preserve cash. The result would undoubtedly lead to a sell-off in the stock. However, if the bank decided to buy back fewer shares, achieving the same preservation of capital as a dividend cut, the stock price would likely take less of a hit.
Committing to dividend payouts with steady increases will undoubtedly drive a company's stock higher, but the dividend strategy can be a double-edged sword. In the event of a recession, share buybacks can be decreased more easily than dividends, with a far less negative impact on the stock price.
The Stock Is Undervalued
Another major motive for businesses to do buybacks is that they genuinely feel as if their shares are undervalued. Undervaluation occurs for several reasons, often due to investors' inability to see past a business' short-term performance, sensationalist news items, or a general bearish sentiment. For example, a wave of stock buybacks swept the United States in 2010 and 2011 when the economy was recovering from the Great Recession.
Many companies began making optimistic forecasts for the coming years, but company stock prices still reflected the economic doldrums that plagued them in years prior. These companies invested in themselves by repurchasing shares, hoping to capitalize when share prices finally began to reflect new, improved economic realities.
If a stock is dramatically undervalued, the issuing company can repurchase some of its shares at this reduced price and then re-issue them once the market has corrected, thereby increasing its equity capital without issuing any additional shares. However, investors may be reluctant to purchase the re-issued shares if they feel they've been burned by a company this way.
RGC Ownership Breakdown
To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. With 81% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
Let's take a closer look to see what the different types of shareholders can tell us about Regencell Bioscience Holdings.
What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company.
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. With such a huge stake, we infer that they have significant control of the future of the company. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.
Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
Most recent data indicates that insiders own the majority of Regencell Bioscience Holdings Limited. This means they can collectively make decisions for the company. So they have a US$430m stake in this US$531m business. Most would be pleased to see the board is investing alongside them.
General Public Ownership
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Equity Ownership
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
https://www.investopedia.com/ask/answers/042015/why-would-company-buyback-its-own-shares.asp#:~:text=A%20company%20repurchases%20its%20shares%20when%20it%20wants%20to%20consolidate,taken%20the%20place%20of%20dividends.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav?utm_medium=article&utm_source=robinhood
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings#information
Biotech stocks have been on a roller-coaster ride, but continue to outperform the broader market.
In 2021, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), Moderna (MRNA) and Johnson & Johnson (JNJ) launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy, inflation and politics took center stage — interest in biotech fell by the wayside. Shares of Investor's Business Daily's biotech industry group largely declined for 16 months.
Until now.
After hitting a six-year low in mid-June, biotech stocks seem to have regained their footing. Shares rose 40% from that point through mid-August, before tapering slightly down. But the slight decline comes amid a steeper dive for the broader market. The group is ranked sixth out of 197 industry groups tracked by Investor's Business Daily. Meanwhile, the pharma group ranks No. 129.
"The sector has started to show signs of a rebound, and we believe several key data events in the coming months as well as any pickup in (mergers and acquisitions), will likely be pivotal in determining whether investor risk appetite will increase and help sustain the recovery," RBC Capital Markets analyst Brian Abrahams said in a recent report.
But it's key to watch specific measures when examining stocks. In terms of fundamental and technical measures as well as 12-month performance, the best biotech stocks today are:
Catalyst Pharmaceuticals (CPRX)
Vertex Pharmaceuticals (VRTX)
Genmab (GMAB)
Neurocrine Biosciences (NBIX)
Supernus Pharmaceuticals (SUPN)
The No. 1 Biotech Stock
Catalyst is the No. 1 biotech stock, leading an industry group of more than 800 companies.
Its only product is Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, or LEMS. LEMS is a rare autoimmune condition that saps muscle strength and often occurs in lung cancer patients.
Though sales are growing, the company is looking to acquire a second or third product — either through an outright buyout or licensing deal.
Now, the biotech stock is extended above a cup base with a buy point at 8.74, MarketSmith.com shows.
Catalyst shares are also on the Tech Leaders list.
Bullishly, CPRX shares have a best-possible Composite Rating of 99, according to IBD Digital. This puts the biotech stock in the top 1% of all stocks in terms of fundamental and technical measures. Its 12-month performance, measured by the Relative Strength Rating, is also in the top 1% of all stocks.
Moving Beyond Cystic Fibrosis
Vertex is one of the biggest biotech stocks in terms of market cap. It ranks fourth behind Amgen (AMGN), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN).
The company is the de facto leader of the cystic fibrosis drug market. Second-quarter sales — dominated by its triple regimen Trikafta — jumped 22% to almost $2.2 billion.
But it's now expanding into other efforts. Vertex is partnered with Crispr Therapeutics (CRSP) on a gene-editing approach to a pair of blood diseases. Further, Vertex recently announced its $320 million plan to buy its partner in diabetes treatment, privately held ViaCyte. The companies are testing a cell replacement drug in type 1 diabetes.
Beyond that, Vertex is testing treatments for liver and kidney diseases, Duchenne muscular dystrophy and pain.
The biotech stock has a perfect Composite Rating and a Relative Strength Rating of 95. But shares are now sitting just below their 50-day moving average.
The company is also a Tech Leader.
Cancer Treatments Are Key
Genmab sells a small handful of treatments for cancer. The company partners with big biopharma names, including AbbVie (ABBV), Johnson & Johnson (JNJ), Horizon Therapeutics (HZNP) and Seagen (SGEN).
In the second quarter, adjusted earnings and sales increased bullishly to 40 cents per share and $440 million, respectively. Both measures also easily topped forecasts.
Now, Genmab on expanding its suite of medicines to new solid tumors and blood cancers.
Shares have a perfect Composite Rating of 98 and a Relative Strength Rating of 73. Genmab is also a Tech Leader.
Gaining Pipeline Recognition
Biotech stock investors are watching catalysts galore for Neurocrine Bio in the second half of 2022 and next year. The company sells a movement disorder treatment called Ingrezza. Ingrezza brought in $350 million in net sales in the second quarter, growing by double digits and beating forecasts.
Neurocrine also raised its Ingrezza sales expectations for the year to $1.35 billion to $1.4 billion.
Meanwhile, the company has a number of drugs in the works for schizophrenia, depression and an adrenal disorder — to name just a few.
The biotech stock's relative strength line is at a 52-week high. Shares also have a promising Composite Rating of 97 and a Relative Strength Rating of 93. Neurocrine stock is forming a flat base with a buy point at 109.36.
Plus, NBIX shares land on the Tech Leaders list.
New Approach To ADHD
Supernus is best known for its migraine prevention drug, Trokendi, but biotech stock investors are also watching the growth trajectory for Qelbree. Qelbree is a non-stimulant treatment for attention deficit hyperactivity disorder, or ADHD. Regulators have approved it for people as young as 6.
In the June quarter, Qelbree prescriptions surged by a third to 62,938. Sales grew 34% to $11.1 million. That helped offset a 9% decline for Trokendi.
The company also is working on treatments for Parkinson's disease, treatment-resistant depression and epilepsy.
The biotech stock recently broke out of a lengthy double-bottom base with an entry at 34.55. Shares slid below their buy point in late August. Since then, they have bounded into and out of the 5% chase zone.
Supernus stock is also a Tech Leader.
There is another biotech stock that is worth to look at which is Regencell Bioscience, $RGC.
As an early-stage bioscience company, Regencell Bioscience is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
374
|
Created
|
02/07/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |